TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of a Novel Dietary Supplement on Visual Function in Patients With Diabetes With and Without Early Diabetic Retinopathy
Brief Summary: This study will evaluate the effects of a novel multi-component dietary supplement on the visual function and retinal structure of patients with diabetes with both no diabetic retinopathy and mild to moderate diabetic retinopathy. This is a placebo-controlled trial and neither subjects nor examiners will know if any given subject is taking active supplement or placebo.

The hypothesis is that the supplement will improve visual function and retinal structure in subjects on active supplement


Options:
A: Arm Label: Product one; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Product two; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Oligopin® | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Product one | Intervention Type: DIETARY_SUPPLEMENT; Name: Oligopin®; Assigned to Arm(s): Product two
B: Arm Label: Pycnogenol; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Pycnogenol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate | Intervention Type: DIETARY_SUPPLEMENT; Name: Pycnogenol; Assigned to Arm(s): Pycnogenol | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Methylphenidate | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Verum; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Verum | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Verum; Assigned to Arm(s): Verum | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: supplement - no retinopathy; Type: EXPERIMENTAL; Interventions: Dietary Supplement: multi-component nutritional supplement capsules | Arm Label: placebo - no retinopathy; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: multi-component dietary supplement | Arm Label: supplement - retinopathy; Type: EXPERIMENTAL; Interventions: Dietary Supplement: multi-component nutritional supplement capsules | Arm Label: placebo - retinopathy; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: multi-component dietary supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: multi-component nutritional supplement capsules; Assigned to Arm(s): supplement - no retinopathy, supplement - retinopathy | Intervention Type: DIETARY_SUPPLEMENT; Name: multi-component dietary supplement; Assigned to Arm(s): placebo - no retinopathy, placebo - retinopathy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Internet-Based Sun Protection Program for Kidney Transplantation Recipients
Brief Summary: This study is being done to evaluate the effectiveness of a Sun Protection Strategies internet-based program for kidney transplant recipients. Since the medication taken to preserve the kidney transplant puts kidney transplant recipients at increased risk of developing a sunburn as well a skin cancer, the program will help people learn how to practice effective sun protection for their condition.


Options:
A: Arm Label: Sun Protection Education; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based sun protection education | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Internet-based sun protection education; Assigned to Arm(s): Sun Protection Education
B: Arm Label: Lay Health Worker Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lay Health Worker Intervention | Arm Label: Placebo (a list of resources); Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Placebo (a list of resources) | Intervention Type: BEHAVIORAL; Name: Lay Health Worker Intervention; Assigned to Arm(s): Lay Health Worker Intervention | Intervention Type: BEHAVIORAL; Name: Placebo (a list of resources); Assigned to Arm(s): Placebo (a list of resources)
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Decision aid and navigation | Intervention Type: BEHAVIORAL; Name: Decision aid and navigation; Assigned to Arm(s): Intervention group
D: Arm Label: Lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Arm Label: Controls; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention; Assigned to Arm(s): Lifestyle intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Internet-Based Sun Protection Program for Kidney Transplantation Recipients
Brief Summary: This study is being done to evaluate the effectiveness of a Sun Protection Strategies internet-based program for kidney transplant recipients. Since the medication taken to preserve the kidney transplant puts kidney transplant recipients at increased risk of developing a sunburn as well a skin cancer, the program will help people learn how to practice effective sun protection for their condition.


Options:
A: Arm Label: Computerised CBT with therapist support; Type: EXPERIMENTAL; Interventions: Behavioral: Computerised Cognitive Behavioural Therapy, Behavioral: Telephone support | Arm Label: Computerised CBT without therapist support; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Computerised Cognitive Behavioural Therapy | Intervention Type: BEHAVIORAL; Name: Computerised Cognitive Behavioural Therapy; Assigned to Arm(s): Computerised CBT with therapist support, Computerised CBT without therapist support | Intervention Type: BEHAVIORAL; Name: Telephone support; Assigned to Arm(s): Computerised CBT with therapist support
B: Arm Label: Multi-component Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Action-focused problem-solving, Device: Electronic pillbox monitoring, dose reminders, and feedback | Arm Label: Attention control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Action-focused problem-solving; Assigned to Arm(s): Multi-component Intervention | Intervention Type: DEVICE; Name: Electronic pillbox monitoring, dose reminders, and feedback; Assigned to Arm(s): Multi-component Intervention
C: Arm Label: Sun Protection Education; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based sun protection education | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Internet-based sun protection education; Assigned to Arm(s): Sun Protection Education
D: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: mHealth; Type: EXPERIMENTAL; Interventions: Behavioral: mHealth | Intervention Type: BEHAVIORAL; Name: mHealth; Assigned to Arm(s): mHealth

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Internet-Based Sun Protection Program for Kidney Transplantation Recipients
Brief Summary: This study is being done to evaluate the effectiveness of a Sun Protection Strategies internet-based program for kidney transplant recipients. Since the medication taken to preserve the kidney transplant puts kidney transplant recipients at increased risk of developing a sunburn as well a skin cancer, the program will help people learn how to practice effective sun protection for their condition.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attention control | Arm Label: B; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Intervention Type: BEHAVIORAL; Name: Attention control; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): B
B: Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: TMITT; Type: ACTIVE_COMPARATOR; Interventions: Other: Transplant Medication Information Teaching Tool | Intervention Type: OTHER; Name: Transplant Medication Information Teaching Tool; Assigned to Arm(s): TMITT
C: Arm Label: Sun Protection Education; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based sun protection education | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Internet-based sun protection education; Assigned to Arm(s): Sun Protection Education
D: Arm Label: Standard of Care (Control); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Patient-Guided; Type: EXPERIMENTAL; Interventions: Other: Patient-Guided | Arm Label: Educator-Guided; Type: EXPERIMENTAL; Interventions: Other: Patient-Guided, Other: Educator-Guided | Intervention Type: OTHER; Name: Patient-Guided; Assigned to Arm(s): Educator-Guided, Patient-Guided | Intervention Type: OTHER; Name: Educator-Guided; Assigned to Arm(s): Educator-Guided

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Introduction of Mealtime Assistance Onto an Acute Medical Ward for Older People
Brief Summary: The primary objective of the study is to determine if the use of volunteers employed specifically to focus on mealtime assistance can increase food and nutrient intake of patients admitted to an acute Care of the Elderly ward. The sustainability of providing helpers to increase dietary intake over a year will be assessed and linked to actual dietary intake. The secondary objectives are to assess the association between dietary intake resulting from mealtime assistance and patient satisfaction, malnutrition risk, body composition, grip strength, length of hospital stay and hospital mortality.


Options:
A: Arm Label: usual mealtime care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: mealtime assistance; Type: EXPERIMENTAL; Interventions: Other: trained volunteer mealtime assistance | Intervention Type: OTHER; Name: trained volunteer mealtime assistance; Assigned to Arm(s): mealtime assistance
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Protein pulse-feeding | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Spread diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Protein pulse-feeding; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Spread diet; Assigned to Arm(s): 2
C: Arm Label: Intervention with energy dense formula; Type: EXPERIMENTAL; Interventions: Other: Calogen® - an energy dense oleic acid based formula | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Calogen® - an energy dense oleic acid based formula; Assigned to Arm(s): Intervention with energy dense formula
D: Arm Label: Ready to drink flavored beverage; Type: PLACEBO_COMPARATOR; Interventions: Other: Ready to Drink Flavored Beverage | Arm Label: Ready to drink flavored beverage w/ AN 777; Type: EXPERIMENTAL; Interventions: Other: Ready to drink flavored beverage w/ AN 777 | Intervention Type: OTHER; Name: Ready to Drink Flavored Beverage; Assigned to Arm(s): Ready to drink flavored beverage | Intervention Type: OTHER; Name: Ready to drink flavored beverage w/ AN 777; Assigned to Arm(s): Ready to drink flavored beverage w/ AN 777

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Controlled, Crossover Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Severe Tourette Syndrome
Brief Summary: The purpose of this study is to investigate whether deep brain stimulation (DBS) of the globus pallidus internum (GPi) can alleviate tics in Gilles de la Tourette syndrome (GTS) and whether this treatment has any influence on social, psychological and behavioral disability and quality of life.


Options:
A: Arm Label: Deep Brain Stimulation; Type: ACTIVE_COMPARATOR; Interventions: Other: Deep brain stimulation | Arm Label: Placebo; Type: SHAM_COMPARATOR; Interventions: Other: Placebo | Intervention Type: OTHER; Name: Deep brain stimulation; Assigned to Arm(s): Deep Brain Stimulation | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: ODT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Optimal drug therapy | Arm Label: DBS+ODT; Type: EXPERIMENTAL; Interventions: Device: B-STN DBS, Drug: Optimal drug therapy | Intervention Type: DEVICE; Name: B-STN DBS; Assigned to Arm(s): DBS+ODT | Intervention Type: DRUG; Name: Optimal drug therapy; Assigned to Arm(s): DBS+ODT, ODT
C: Arm Label: DBS Off first; Type: EXPERIMENTAL; Interventions: Procedure: Bilateral GPi Deep Brain Stimulation | Arm Label: DBS On First; Type: EXPERIMENTAL; Interventions: Procedure: Bilateral GPi Deep Brain Stimulation | Intervention Type: PROCEDURE; Name: Bilateral GPi Deep Brain Stimulation; Assigned to Arm(s): DBS Off first, DBS On First
D: Intervention Type: DEVICE; Name: high frequency stimulation; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo Controlled Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of Induction Therapy With RPC1063 in Patients With Moderately to Severely Active Ulcerative Colitis
Brief Summary: The purpose of this study is to determine whether RPC1063 is effective in the treatment of ulcerative colitis (UC).


Options:
A: Arm Label: 1: budesonide-MMX® 6 mg; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling, endoscopy, Drug: budesonide-MMX® 6 mg | Arm Label: 2: budesonide-MMX® 9 mg; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling, endoscopy, Drug: budesonide-MMX® 9 mg | Arm Label: 3: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Blood sampling, endoscopy, Drug: Placebo | Arm Label: 4: Asacol® 400 mg; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Blood sampling, endoscopy, Drug: Asacol® 400 mg | Intervention Type: PROCEDURE; Name: Blood sampling, endoscopy; Assigned to Arm(s): 1: budesonide-MMX® 6 mg, 2: budesonide-MMX® 9 mg, 3: Placebo, 4: Asacol® 400 mg | Intervention Type: DRUG; Name: budesonide-MMX® 6 mg; Assigned to Arm(s): 1: budesonide-MMX® 6 mg | Intervention Type: DRUG; Name: budesonide-MMX® 9 mg; Assigned to Arm(s): 2: budesonide-MMX® 9 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3: Placebo | Intervention Type: DRUG; Name: Asacol® 400 mg; Assigned to Arm(s): 4: Asacol® 400 mg
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Granulated mesalamine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Granulated mesalamine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Ozanimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod | Arm Label: Ozanimod 1 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ozanimod; Assigned to Arm(s): Ozanimod 0.5 mg, Ozanimod 1 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Golimumab 1 milligram (mg) per kilogram (kg); Type: EXPERIMENTAL; Interventions: Drug: Golimumab 1 mg per kg | Arm Label: Golimumab 2 mg per kg; Type: EXPERIMENTAL; Interventions: Drug: Golimumab 2 mg per kg | Arm Label: Golimumab 4 mg per kg; Type: EXPERIMENTAL; Interventions: Drug: Golimumab 4 mg per kg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Golimumab 1 mg per kg; Assigned to Arm(s): Golimumab 1 milligram (mg) per kilogram (kg) | Intervention Type: DRUG; Name: Golimumab 2 mg per kg; Assigned to Arm(s): Golimumab 2 mg per kg | Intervention Type: DRUG; Name: Golimumab 4 mg per kg; Assigned to Arm(s): Golimumab 4 mg per kg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Experimentation of New Organizational Models of Cervical Cancer Screening Programs, Upon the Use of HPV Test as First Level: Evaluation of the Methodologies Proposed of the Use of Self-sampling Devices to Recover Non-responders.
Brief Summary: The opportunity of a home, self-collected sample, opens the chance to remove some of the barriers that may discourage women from participating to screening programmes or performing HPV (Human Papilloma Virus)-test. Self-sampling is less time consuming and invasive as compared with tests performed at a clinic. It allows for privacy, reduces discomfort and women know nobody would have to handle their body.

Study hypothesis: The use of a self-sampler may increase the recovery of non-responders women at cervical cancer screening.


Options:
A: Arm Label: Usual Care Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care Group | Arm Label: Lay Health Advisor Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lay Health Advisor Education Intervention | Intervention Type: BEHAVIORAL; Name: Lay Health Advisor Education Intervention; Assigned to Arm(s): Lay Health Advisor Intervention | Intervention Type: BEHAVIORAL; Name: Usual Care Group; Assigned to Arm(s): Usual Care Group
B: Arm Label: Motivational SMS; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational SMS | Arm Label: Travel Voucher; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational SMS, Behavioral: Travel Voucher | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Motivational SMS; Assigned to Arm(s): Motivational SMS, Travel Voucher | Intervention Type: BEHAVIORAL; Name: Travel Voucher; Assigned to Arm(s): Travel Voucher
C: Arm Label: control 1; Type: N/A; Interventions: N/A | Arm Label: Intervention 1; Type: N/A; Interventions: N/A | Arm Label: intervention 2; Type: N/A; Interventions: N/A
D: Arm Label: Early Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lay health advisor visits and newsletter | Arm Label: Delayed Intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Lay health advisor visits and newsletter; Assigned to Arm(s): Early Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II/III Study to Investigate the Effects of Fingolimod Versus Interferon Beta-1b on Visual Recovery After Optic Neuritis
Brief Summary: In the MOVING study should be examined, whether early therapeutic intervention with fingolimod (Gilenya ®) after optic neuritis(ON) has a favorable visual outcome as a comparative therapie with Interferon beta-1b (Extavia®), as measured by multifocal visual evoked potentials (mVEP) after 6 month compared to baseline.


Options:
A: Arm Label: Interferon beta-1a 44 mcg SC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta-1a, Drug: Ocrelizumab-matching placebo | Arm Label: Ocrelizumab; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab, Drug: Interferon beta-1a-matching placebo | Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab-matching placebo; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab | Intervention Type: DRUG; Name: Interferon beta-1a-matching placebo; Assigned to Arm(s): Ocrelizumab
B: Arm Label: Atacicept 25 mg; Type: EXPERIMENTAL; Interventions: Drug: Atacicept | Arm Label: Atacicept 75 mg; Type: EXPERIMENTAL; Interventions: Drug: Atacicept | Arm Label: Atacicept 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Atacicept | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo matched to atacicept | Intervention Type: DRUG; Name: Atacicept; Assigned to Arm(s): Atacicept 25 mg | Intervention Type: DRUG; Name: Atacicept; Assigned to Arm(s): Atacicept 75 mg | Intervention Type: DRUG; Name: Atacicept; Assigned to Arm(s): Atacicept 150 mg | Intervention Type: DRUG; Name: Placebo matched to atacicept; Assigned to Arm(s): Placebo
C: Arm Label: Fingolimod (Gilenya®); Type: EXPERIMENTAL; Interventions: Drug: Verum arm receiving Gilenya® | Arm Label: Interferon beta-1b (Extavia®); Type: ACTIVE_COMPARATOR; Interventions: Drug: Active Comparator receiving Extavia® | Intervention Type: DRUG; Name: Verum arm receiving Gilenya®; Assigned to Arm(s): Fingolimod (Gilenya®) | Intervention Type: DRUG; Name: Active Comparator receiving Extavia®; Assigned to Arm(s): Interferon beta-1b (Extavia®)
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Ocrelizumab 600 mg; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab | Arm Label: Ocrelizumab 1000 mg; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab | Arm Label: Avonex; Type: ACTIVE_COMPARATOR; Interventions: Drug: Avonex | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab 1000 mg, Ocrelizumab 600 mg | Intervention Type: DRUG; Name: Avonex; Assigned to Arm(s): Avonex

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transfusion Requirements in Critical Clinical Oncologic Patients: a Phase 3 Randomized Controlled Clinical Trial (TRICCOP STUDY)
Brief Summary: Blood transfusion in critical ill patients has been associated to several complications and worse outcome. Particularly in oncologic patients, red blood cell transfusion has been investigated as a factor of worse outcome and cancer recurrence due impairment of cellular immunity. Although red blood cell transfusion has decreased in worldwide clinical practice, this issue still remains a matter of controversy in oncologic patients. There are no prospective studies comparing outcomes between restrictive or liberal blood transfusion strategy in oncologic critical patients. This study is a prospective and randomized study comparing clinical outcomes between two strategies of transfusion in oncologic critical patients - liberal or restrictive.


Options:
A: Arm Label: Blood transfusion; Type: EXPERIMENTAL; Interventions: Biological: Blood transfusion | Intervention Type: BIOLOGICAL; Name: Blood transfusion; Assigned to Arm(s): Blood transfusion
B: Arm Label: Liberal Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Arm Label: Restrictive Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Liberal Transfusion Strategy | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Restrictive Transfusion Strategy
C: Arm Label: Low transfusion threshold; Type: EXPERIMENTAL; Interventions: Biological: Red blood cell transfusion | Arm Label: High transfusion threshold; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell transfusion | Intervention Type: BIOLOGICAL; Name: Red blood cell transfusion; Assigned to Arm(s): High transfusion threshold, Low transfusion threshold
D: Arm Label: Liberal Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell transfusion | Arm Label: Restrictive Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell transfusion | Intervention Type: BIOLOGICAL; Name: Red blood cell transfusion; Assigned to Arm(s): Liberal Transfusion Strategy | Intervention Type: BIOLOGICAL; Name: Red blood cell transfusion; Assigned to Arm(s): Restrictive Transfusion Strategy

Answer: D